SCHEMBL851652

SCHEMBL851652

NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(I)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 2/20 0.53
AKT1 P31749 2/20 0.53
AKT2 P31751 2/20 0.53
AKT3 Q9Y243 2/20 0.53
ROCK2 O75116 1/20 0.53
RPS6KA5 O75582 1/20 0.53
RPS6KA4 O75676 1/20 0.53
LATS1 O95835 1/20 0.53
PRKACB P22694 1/20 0.53
RPS6KB1 P23443 1/20 0.53
GRK2 P25098 1/20 0.53
RPS6KA3 P51812 1/20 0.53
PRKCD Q05655 1/20 0.53
ROCK1 Q13464 1/20 0.53
RPS6KA2 Q15349 1/20 0.53
RPS6KA1 Q15418 1/20 0.53
PKN1 Q16512 1/20 0.53
PKN2 Q16513 1/20 0.53
SGK3 Q96BR1 1/20 0.53
RPS6KB2 Q9UBS0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851350 1.00 PRKACA (0.53) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL851562 1.00 PRKACA (0.53) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL243249 0.90 PRKACA (0.60) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL12157320 0.81 NPSR1 (0.49) TSHRCYP1A2CYP3A4NPSR1BCL2
SCHEMBL850795 0.81 CYP1A2 (0.44) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL3029777 0.79 NPSR1 (0.47) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL3025831 0.78 MIF (0.65) TSHRNPSR1BCL2MEN1KMT2A
SCHEMBL12157315 0.77 NPSR1 (0.57) TSHRCYP1A2CYP3A4NPSR1BCL2
SCHEMBL3025609 0.77 NPSR1 (0.41) PRKACAAKT1AKT2AKT3ROCK2
SCHEMBL4452093 0.74 APP (0.39) TSHRCYP1A2CYP3A4MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497294-B2 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases ASTEX THERAPEUTICS LIMITED (GB) 2013-07-30 US disclosed
EP-2433632-A1 Compositions and combinations comprising non-racemic 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, for use in medicine Astex Therapeutics Limited (GB) 2012-03-28 EP disclosed
US-20110269808-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2011-11-03 US disclosed
US-20100113551-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-05-06 US disclosed
EP-2134339-A2 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES Astex Therapeutics Limited (GB) 2009-12-23 EP disclosed
WO-2008110846-A2 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113551-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES MAP4K2, PRKCH, DSTYK PRKACA 51/4885AKT1 180/4885AKT2 302/4885
US-20110269808-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES MAP4K2, MAP4K1, PRKCH PRKACA 78/4885AKT1 214/4885AKT2 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.